TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from SSY Group ( (HK:2005) ).
SSY Group Limited has announced that its Ambroxol Hydrochloride has received approval from China’s National Medical Products Administration to be marketed as a bulk drug. This development signifies a significant advancement in the company’s product offerings, potentially enhancing its market position in the respiratory treatment sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company’s primary products include drugs and treatments for various health conditions, with a market focus on respiratory diseases.
YTD Price Performance: -7.62%
Average Trading Volume: 14,295,131
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.27B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.